US priority review for Keytruda/chemo combo in first-line squamous NSCLC
US regulators have assigned a priority review to MSD’s application to market the immunotherapy Keytruda in combination with chemotherapy as a first-line treatment for squamous non-small cell lung cancer (NSCLC).
The application is based on data from the Phase III KEYNOTE-407 trial, in which Keytruda (pembrolizumab) plus chemotherapy cut the risk of death by 36 percent compared to chemotherapy alone, when used as a first-line treatment for patients with metastatic squamous NSCLC.
The addition of Keytruda to chemotherapy also significantly improved progression-free survival (PFS), with a reduction in the risk of disease progression or death of 44 percent, according to the results.
Read more: http://www.pharmatimes.com/news/us_priority_review_for_keytrudachemo_combo_in_first-line_squamous_nsclc_1243027
The application is based on data from the Phase III KEYNOTE-407 trial, in which Keytruda (pembrolizumab) plus chemotherapy cut the risk of death by 36 percent compared to chemotherapy alone, when used as a first-line treatment for patients with metastatic squamous NSCLC.
The addition of Keytruda to chemotherapy also significantly improved progression-free survival (PFS), with a reduction in the risk of disease progression or death of 44 percent, according to the results.
Read more: http://www.pharmatimes.com/news/us_priority_review_for_keytrudachemo_combo_in_first-line_squamous_nsclc_1243027